Q4 2024 IRadimed Corp Earnings Call Transcript
Key Points
- iRadimed Corp (IRMD) reported a record quarter with revenue exceeding $19.4 million, marking the 14th consecutive record quarter.
- Gross profit was strong at 76.1%, with GAAP diluted earnings per share increasing by 11% from Q4 2023.
- Domestic sales increased by 21% to $16.5 million, accounting for 85% of total revenue for Q4 2024.
- The company has a strong backlog entering 2025, providing good visibility for the first half of the year.
- The new facility construction is progressing well, with completion expected by June, which will support future growth.
- International sales decreased by 24% to $2.9 million, indicating challenges in global markets.
- The gross margin for Q4 2024 was slightly below the previous year's quarter, at 76.1% compared to 76.9%.
- Operating expenses increased to $9 million, driven by higher sales and marketing expenses.
- Free cash flow decreased to $2.9 million from $3.3 million in the same period in 2023, due to ongoing capital expenditures.
- The company faces potential delays in FDA clearance for the new pump, which could impact revenue projections for 2025.
Welcome to the IRADIMED corporation fourth quarter of 2024 financial results conference call. (Operator Instructions) This call is being recorded today, February 13, 2025 and contains time-sensitive accurate information only today.
Earlier, IRADIMED released its financial results for the fourth quarter of 2024. A copy of this press release announcing the company's earnings is available under the heading news on their website at iradimed.com. A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov. This call is being broadcast live over the Internet on the company's website at iradimed.com, and a replay will be available on the website for the next 90 days.
Some of the information in today's session will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements focus on future performance, results, plans, and events that may include the company's expected future results. IRADIMED reminds you that future results may differ materially
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
